Cristina Hernandez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3884284/publications.pdf

Version: 2024-02-01

		36303	56724
205	9,225	51	83
papers	citations	h-index	g-index
213	213	213	10452
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	ERM Complex, A Therapeutic Target for Vascular Leakage Induced by Diabetes. Current Medicinal Chemistry, 2022, 29, 2189-2199.	2.4	2
2	Perinatal famine is associated with excess risk of proliferative retinopathy in patients with type 2 diabetes. Acta Ophthalmologica, 2022, 100, .	1.1	5
3	Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study. Diabetes, 2022, 71, 315-320.	0.6	19
4	Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. Trends in Endocrinology and Metabolism, 2022, 33, 50-71.	7.1	34
5	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Advances, 2022, 6, 774-784.	5.2	42
6	Phenotyping Type 2 Diabetes in Terms of Myocardial Insulin Resistance and Its Potential Cardiovascular Consequences: A New Strategy Based on 18F-FDG PET/CT. Journal of Personalized Medicine, 2022, 12, 30.	2.5	2
7	Deep Learning of Retinal Imaging: A Useful Tool for Coronary Artery Calcium Score Prediction in Diabetic Patients. Applied Sciences (Switzerland), 2022, 12, 1401.	2.5	7
8	Minimum Effective Dose of DPP-4 Inhibitors for Treating Early Stages of Diabetic Retinopathy in an Experimental Model. Biomedicines, 2022, 10, 465.	3.2	3
9	Prediabetes Is Associated with Increased Prevalence of Sleep-Disordered Breathing. Journal of Clinical Medicine, 2022, 11, 1413.	2.4	5
10	Diabetic Retinopathy: Role of Neurodegeneration and Therapeutic Perspectives. Asia-Pacific Journal of Ophthalmology, 2022, 11, 160-167.	2.5	14
11	Neuronal Dysfunction Is Linked to the Famine-Associated Risk of Proliferative Retinopathy in Patients With Type 2 Diabetes. Frontiers in Neuroscience, 2022, 16, .	2.8	1
12	Advanced Glycations End Products in the Skin as Biomarkers of Cardiovascular Risk in Type 2 Diabetes. International Journal of Molecular Sciences, 2022, 23, 6234.	4.1	4
13	Metabolic footprint of aging and obesity in red blood cells. Aging, 2021, 13, 4850-4880.	3.1	7
14	Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial. Diabetes Care, 2021, 44, 1604-1612.	8.6	27
15	Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes. Acta Diabetologica, 2021, 58, 1403-1412.	2.5	6
16	Standardization of Optical Coherence Tomography Angiography Imaging Biomarkers in Diabetic Retinal Disease. Ophthalmic Research, 2021, 64, 871-887.	1.9	19
17	The Gaze Fixation Assessed by Microperimetry: A Useful Tool for the Monitoring of the Cognitive Function in Patients with Type 2 Diabetes. Journal of Personalized Medicine, 2021, 11, 698.	2.5	4
18	Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes. Biomedicines, 2021, 9, 926.	3.2	12

#	Article	IF	CITATIONS
19	Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy. Pharmaceutics, 2021, 13, 1320.	4.5	30
20	A Clinical-Genetic Score for Predicting Weight Loss after Bariatric Surgery: The OBEGEN Study. Journal of Personalized Medicine, 2021, 11, 1040.	2.5	13
21	Neuromodulation Induced by Sitagliptin: A New Strategy for Treating Diabetic Retinopathy. Biomedicines, 2021, 9, 1772.	3.2	6
22	Diabetic Retinopathy and Skin Tissue Advanced Glycation End Products Are Biomarkers of Cardiovascular Events in Type 2 Diabetic Patients. Journal of Personalized Medicine, 2021, 11, 1344.	2.5	2
23	Caffeine Upregulates Hepatic Sex Hormoneâ€Binding Globulin Production by Increasing Adiponectin Through AKT/FOXO1 Pathway in White Adipose Tissue. Molecular Nutrition and Food Research, 2020, 64, e1901253.	3.3	4
24	Effect of Topical Administration of Somatostatin on Retinal Inflammation and Neurodegeneration in an Experimental Model of Diabetes. Journal of Clinical Medicine, 2020, 9, 2579.	2.4	15
25	Effect of Type 2 Diabetes Mellitus on the Hypoxia-Inducible Factor 1-Alpha Expression. Is There a Relationship with the Clock Genes?. Journal of Clinical Medicine, 2020, 9, 2632.	2.4	4
26	Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain. Journal of Clinical Medicine, 2020, 9, 2726.	2.4	4
27	Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: Involvement of Oxidative Stress. Antioxidants, 2020, 9, 846.	5.1	21
28	A Translational In Vivo and In Vitro Metabolomic Study Reveals Altered Metabolic Pathways in Red Blood Cells of Type 2 Diabetes. Journal of Clinical Medicine, 2020, 9, 1619.	2.4	15
29	Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic. Scientific Reports, 2020, 10, 1580.	3.3	22
30	Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes and Endocrinology,the, 2020, 8, 337-347.	11.4	288
31	The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial. Journal of Clinical Medicine, 2020, 9, 1233.	2.4	10
32	Effect of Subcutaneous Insulin on Spirometric Maneuvers in Patients with Type 1 Diabetes: A Case-Control Study. Journal of Clinical Medicine, 2020, 9, 1249.	2.4	2
33	Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative. Alzheimer's Research and Therapy, 2020, 12, 37.	6.2	24
34	Effect of Glucose Improvement on Nocturnal Sleep Breathing Parameters in Patients with Type 2 Diabetes: The Candy Dreams Study. Journal of Clinical Medicine, 2020, 9, 1022.	2.4	7
35	The ERM Complex: A New Player Involved in Diabetes-induced Vascular Leakage. Current Medicinal Chemistry, 2020, 27, 3012-3022.	2.4	4
36	Genetic Testing to Predict Weight Loss and Diabetes Remission and Long-Term Sustainability after Bariatric Surgery: A Pilot Study. Journal of Clinical Medicine, 2019, 8, 964.	2.4	13

#	Article	IF	CITATIONS
37	SOCS1-Derived Peptide Administered by Eye Drops Prevents Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes. International Journal of Molecular Sciences, 2019, 20, 3615.	4.1	25
38	Usefulness of Liquid Biopsy Biomarkers from Aqueous Humor in Predicting Anti-VEGF Response in Diabetic Macular Edema: Results of a Pilot Study. Journal of Clinical Medicine, 2019, 8, 1841.	2.4	25
39	Characteristics of atheromatosis in the prediabetes stage: a cross-sectional investigation of the ILERVAS project. Cardiovascular Diabetology, 2019, 18, 154.	6.8	17
40	Sympathetic Hyperactivity and Sleep Disorders in Individuals With Type 2 Diabetes. Frontiers in Endocrinology, 2019, 10, 752.	3.5	5
41	Assessment of Inner Retinal Layers and Choroidal Thickness in Type 1 Diabetes Mellitus: A Cross-Sectional Study. Journal of Clinical Medicine, 2019, 8, 1412.	2.4	21
42	Effect of Glucose Improvement on Spirometric Maneuvers in Patients With Type 2 Diabetes: The Sweet Breath Study. Diabetes Care, 2019, 42, 617-624.	8.6	15
43	Visual impairment in aging and cognitive decline: experience in a Memory Clinic. Scientific Reports, 2019, 9, 8698.	3.3	32
44	Diabetic Retinopathy in the Context of Patients with Diabetes. Ophthalmic Research, 2019, 62, 211-217.	1.9	130
45	Topical Treatment With Brimonidine and Somatostatin Causes Retinal Vascular Dilation in Patients With Early Diabetic Retinopathy From the EUROCONDOR. , 2019, 60, 2257.		18
46	Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project. Journal of Atherosclerosis and Thrombosis, 2019, 26, 879-889.	2.0	9
47	Lung function measurements in the prediabetes stage: data from the ILERVAS Project. Acta Diabetologica, 2019, 56, 1005-1012.	2.5	11
48	Sex Hormone–Binding Globulin Expression Correlates With Acetyl-Coenzyme A Carboxylase and Triglyceride Content in Human Liver. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1500-1507.	3.6	26
49	New Insights into the Mechanisms of Action of Topical Administration of GLP-1 in an Experimental Model of Diabetic Retinopathy. Journal of Clinical Medicine, 2019, 8, 339.	2.4	34
50	Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study. BMJ Open Diabetes Research and Care, 2019, 7, e000845.	2.8	24
51	Retinal Microperimetry: A Useful Tool for Detecting Insulin Resistance-Related Cognitive Impairment in Morbid Obesity. Journal of Clinical Medicine, 2019, 8, 2181.	2.4	5
52	Diabetische Retinopathie bei Patienten mit Diabetes mellitus. Karger Kompass Ophthalmologie, 2019, 5, 157-162.	0.0	0
53	Comment on: "Glucagonâ€like peptideâ€1 receptor expression in the human eyeâ€. Diabetes, Obesity and Metabolism, 2019, 21, 446-447.	4.4	1
54	Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial. Diabetes, 2019, 68, 457-463.	0.6	69

#	Article	IF	CITATIONS
55	Usefulness of Eye Fixation Assessment for Identifying Type 2 Diabetic Subjects at Risk of Dementia. Journal of Clinical Medicine, 2019, 8, 59.	2.4	15
56	Somatostatin and diabetic retinopathy: an evolving story. Endocrine, 2018, 60, 1-3.	2.3	13
5 7	Response to oral sucrosomial iron supplementation in patients undergoing bariatric surgery. The BARI-FER study. Endocrinologia, Diabetes Y NutriciÓn, 2018, 65, 17-20.	0.3	16
58	Silymarin prevents diabetes-induced hyperpermeability in human retinal endothelial cells. Endocrinologia, Diabetes Y NutriciÓn, 2018, 65, 200-205.	0.3	11
59	A compartmentalized microfluidic chip with crisscross microgrooves and electrophysiological electrodes for modeling the blood–retinal barrier. Lab on A Chip, 2018, 18, 95-105.	6.0	61
60	Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes. International Journal of Molecular Sciences, 2018, 19, 3578.	4.1	21
61	Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease. Scientific Reports, 2018, 8, 16345.	3.3	52
62	Assessment of advanced glycation end-products as a biomarker of diabetic outcomes. Endocrinologia, Diabetes Y NutriciÓn, 2018, 65, 540-545.	0.3	19
63	Assessment of advanced glycation end-products as a biomarker of diabetic outcomes. EndocrinologÃa Diabetes Y Nutrición (English Ed), 2018, 65, 540-545.	0.2	3
64	Silymarin prevents diabetes-induced hyperpermeability in human retinal endothelial cells. EndocrinologÃa Diabetes Y Nutrición (English Ed), 2018, 65, 200-205.	0.2	0
65	Metabolic fingerprint of insulin resistance in human polymorphonuclear leucocytes. PLoS ONE, 2018, 13, e0199351.	2.5	9
66	Effects of Liposomal Formulation of Citicoline in Experimental Diabetes-Induced Retinal Neurodegeneration. International Journal of Molecular Sciences, 2018, 19, 2458.	4.1	22
67	Proteomic Analysis of Early Diabetic Retinopathy Reveals Mediators of Neurodegenerative Brain Diseases. , 2018, 59, 2264.		91
68	Sleep biosignature of Type 2 diabetes: a case–control study. Diabetic Medicine, 2017, 34, 79-85.	2.3	9
69	Cognitive impairment and dementia: a new emerging complication of type 2 diabetes—The diabetologist's perspective. Acta Diabetologica, 2017, 54, 417-424.	2.5	127
70	Type 2 diabetes is an independent risk factor for dementia conversion in patients with mild cognitive impairment. Journal of Diabetes and Its Complications, 2017, 31, 1272-1274.	2.3	54
71	Type 2 diabetes, risk of sleep apnea-hypopnea syndrome, and quality of life associated to sleep breathing disorders. EndocrinologÃa Diabetes Y Nutrición (English Ed), 2017, 64, 174-176.	0.2	0
72	GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?. Diabetes, 2017, 66, 1453-1460.	0.6	55

#	Article	IF	CITATIONS
73	Type 2 diabetes, risk of sleep apnea-hypopnea syndrome, and quality of life associated to sleep breathing disorders. Endocrinologia, Diabetes Y NutriciÓn, 2017, 64, 174-176.	0.3	0
74	Sex Hormone-Binding Globulin Reduction in Metabolic Disorders May Play a Role in NAFLD Development. Endocrinology, 2017, 158, 545-559.	2.8	38
75	Retinal Microperimetry: A New Tool for Identifying Patients With Type 2 Diabetes at Risk for Developing Alzheimer Disease. Diabetes, 2017, 66, 3098-3104.	0.6	35
76	Pulmonary Function and Sleep Breathing: Two New Targets for Type 2 Diabetes Care. Endocrine Reviews, 2017, 38, 550-573.	20.1	55
77	DNA Methylomes Reveal Biological Networks Involved in Human Eye Development, Functions and Associated Disorders. Scientific Reports, 2017, 7, 11762.	3.3	44
78	Calcium dobesilate prevents the oxidative stress and inflammation induced by diabetes in the retina of db/db mice. Journal of Diabetes and Its Complications, 2017, 31, 1481-1490.	2.3	26
79	Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia, 2017, 60, 2285-2298.	6.3	67
80	Calcium Dobesilate Prevents Neurodegeneration and Vascular Leakage in Experimental Diabetes. Current Eye Research, 2017, 42, 1273-1286.	1.5	29
81	Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Project. Diabetes, 2017, 66, 2503-2510.	0.6	103
82	Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial. Endocrine, 2017, 57, 83-88.	2.3	30
83	Serum Surfactant Protein D as a Biomarker for Measuring Lung Involvement in Obese Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4109-4116.	3.6	23
84	Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society). Journal of Ophthalmology, 2017, 2017, 1-10.	1.3	54
85	Type 1 diabetes: Developing the first risk-estimation model for predicting silent myocardial ischemia. The potential role of insulin resistance. PLoS ONE, 2017, 12, e0174640.	2.5	8
86	Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy. , 2017, 58, 3189.		30
87	Mechanisms of retinal neuroprotection of calcium dobesilate: therapeutic implications. Neural Regeneration Research, 2017, 12, 1620.	3.0	8
88	Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes. Diabetes, 2016, 65, 172-187.	0.6	168
89	Neuroprotection as a Therapeutic Target for Diabetic Retinopathy. Journal of Diabetes Research, 2016, 2016, 1-18.	2.3	71
90	Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology. Journal of Diabetes Research, 2016, 2016, 1-13.	2.3	66

#	Article	IF	CITATIONS
91	Gene expression profiling in hearts of diabetic mice uncovers a potential role of estrogen-related receptor Î ³ in diabetic cardiomyopathy. Molecular and Cellular Endocrinology, 2016, 430, 77-88.	3.2	9
92	Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naÃ⁻ve patients with type 2 diabetes: a pilot randomized trial. Lipids in Health and Disease, 2016, 15, 78.	3.0	103
93	Effects of the neuroprotective drugs somatostatin and brimonidine on retinal cell models of diabetic retinopathy. Acta Diabetologica, 2016, 53, 957-964.	2.5	19
94	Nuevos tratamientos para laÂdiabetes mellitus tipoÂ2 y enfermedad cardiovascular. LaÂrevolución yaÂha empezado. Revista Espanola De Cardiologia, 2016, 69, 1005-1007.	1.2	2
95	Modulation of microglia polarization dynamics during diabetic retinopathy in db / db mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1663-1674.	3.8	80
96	geoRge: A Computational Tool To Detect the Presence of Stable Isotope Labeling in LC/MS-Based Untargeted Metabolomics. Analytical Chemistry, 2016, 88, 621-628.	6.5	67
97	Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-lºB activity. Acta Diabetologica, 2016, 53, 109-118.	2.5	28
98	Global Assessment of the Impact of Type 2 Diabetes on Sleep through Specific Questionnaires. A Case-Control Study. PLoS ONE, 2016, 11, e0157579.	2.5	29
99	Somatostatin protects photoreceptor cells against high glucose-induced apoptosis. Molecular Vision, 2016, 22, 1522-1531.	1.1	18
100	Characterization of Sleep Breathing Pattern in Patients with Type 2 Diabetes: Sweet Sleep Study. PLoS ONE, 2015, 10, e0119073.	2.5	18
101	Novel insights in SHBG regulation and clinical implications. Trends in Endocrinology and Metabolism, 2015, 26, 376-383.	7.1	210
102	Effect of glycemic control on nocturnal arterial oxygen saturation: A caseâ€control study in type 2 diabetic patients èj€ç³–控å^¶å⁻¹åæé— 动脉èj€æ°§é¥±å'Œåº¦çš"影哥¼šä,€éj¹2型糖尿病æ,£è€…ç	š" <u>1.8</u> ä¾	≪å ¹⁷ ç§ç"ç©
103	Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?. Current Diabetes Reports, 2015, 15, 24.	4.2	14
104	Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes. Acta Diabetologica, 2015, 52, 113-122.	2.5	45
105	Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Progress in Retinal and Eye Research, 2015, 48, 160-180.	15.5	196
106	Photocoagulation of human retinal pigment epithelium <i>in vitro</i> : unravelling the effects on <scp>ARPE</scp> â€19 by transcriptomics and proteomics. Acta Ophthalmologica, 2015, 93, 348-354.	1.1	6
107	Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy. Experimental Eye Research, 2015, 140, 124-129.	2.6	26
108	SHBG-C57BL/ksJ-db/db: A New Mouse Model to Study SHBG Expression and Regulation During Obesity Development. Endocrinology, 2015, 156, 4571-4581.	2.8	23

#	Article	IF	CITATIONS
109	Thyroid Hormone Upregulates Zinc-α2-glycoprotein Production in the Liver but Not in Adipose Tissue. PLoS ONE, 2014, 9, e85753.	2.5	11
110	The db/db Mouse: A Useful Model for the Study of Diabetic Retinal Neurodegeneration. PLoS ONE, 2014, 9, e97302.	2.5	156
111	Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus. Circulation, 2014, 129, 999-1008.	1.6	197
112	Oleic acid increases hepatic sex hormone binding globulin production in men. Molecular Nutrition and Food Research, 2014, 58, 760-767.	3.3	20
113	Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends in Endocrinology and Metabolism, 2014, 25, 23-33.	7.1	381
114	Glycogen storage in the human retinal pigment epithelium: a comparative study of diabetic and non-diabetic donors. Acta Diabetologica, 2014, 51, 543-552.	2.5	16
115	Adiponectin Upregulates SHBC Production: Molecular Mechanisms and Potential Implications. Endocrinology, 2014, 155, 2820-2830.	2.8	66
116	Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives. Endocrine, 2014, 46, 209-214.	2.3	37
117	Neurodegeneration in diabetic retinopathy: Current concepts and therapeutic implications. Avances En DiabetologÃa, 2014, 30, 72-79.	0.1	2
118	Identification of new pathogenic candidates for diabetic macular edema using fluorescenceâ€based difference gel electrophoresis analysis. Diabetes/Metabolism Research and Reviews, 2013, 29, 499-506.	4.0	17
119	Non-islet cell induced hypoglycemia by "big-IGF-2―in a patient with retroperitoneal solitary fibrous tumor and a papillary thyroid carcinoma: An unusual association. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2013, 60, 483-484.	0.8	3
120	Testosterone induces cell proliferation and cell cycle gene overexpression in human visceral preadipocytes. American Journal of Physiology - Cell Physiology, 2013, 305, C355-C359.	4.6	31
121	Overexpression of Hemopexin in the Diabetic Eye. Diabetes Care, 2013, 36, 2815-2821.	8.6	14
122	Topical Administration of Somatostatin Prevents Retinal Neurodegeneration in Experimental Diabetes. Diabetes, 2013, 62, 2569-2578.	0.6	109
123	Molecular Implications of the PPARs in the Diabetic Eye. PPAR Research, 2013, 2013, 1-11.	2.4	22
124	Impact of Glucose-Lowering Agents on the Risk of Cancer in Type 2 Diabetic Patients. The Barcelona Case-Control Study. PLoS ONE, 2013, 8, e79968.	2.5	29
125	Genetics in Diabetic Retinopathy: Current Concepts and New Insights. Current Genomics, 2013, 14, 289-299.	1.6	62
126	Diabetes Protects from Prostate Cancer by Downregulating Androgen Receptor: New Insights from LNCaP Cells and PAC120 Mouse Model. PLoS ONE, 2013, 8, e74179.	2.5	22

#	Article	IF	CITATIONS
127	Somatostatin Replacement: A New Strategy for Treating Diabetic Retinopathy. Current Medicinal Chemistry, 2013, 20, 3251-3257.	2.4	17
128	Proapoptotic and survival signaling in the neuroretina at early stages of diabetic retinopathy. Molecular Vision, 2013, 19, 47-53.	1.1	39
129	Usefulness of the Vitreous Fluid Analysis in the Translational Research of Diabetic Retinopathy. Mediators of Inflammation, 2012, 2012, 1-11.	3.0	75
130	Potential Role of Tumor Necrosis Factor-α in Downregulating Sex Hormone–Binding Globulin. Diabetes, 2012, 61, 372-382.	0.6	102
131	Update on Cardiovascular Safety of PPARgamma Agonists and Relevance to Medicinal Chemistry and Clinical Pharmacology. Current Topics in Medicinal Chemistry, 2012, 12, 585-604.	2.1	27
132	Molecular Mechanism of TNFα-Induced Down-Regulation of SHBG Expression. Molecular Endocrinology, 2012, 26, 438-446.	3.7	50
133	IL1β Down-regulation of Sex Hormone-Binding Globulin Production by Decreasing HNF-4α Via MEK-1/2 and JNK MAPK Pathways. Molecular Endocrinology, 2012, 26, 1917-1927.	3.7	61
134	Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. British Journal of Ophthalmology, 2012, 96, 1285-1290.	3.9	128
135	Non-Invasive Methods of Glucose Measurement: Current Status and Future Perspectives. Current Diabetes Reviews, 2012, 8, 48-54.	1.3	54
136	Prevention and Treatment of Diabetic Retinopathy: Evidence from Large, Randomized Trials. The Emerging Role of Fenofibrate. Reviews on Recent Clinical Trials, 2012, 7, 71-80.	0.8	24
137	Neuroprotection in Diabetic Retinopathy. Current Diabetes Reports, 2012, 12, 329-337.	4.2	59
138	Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy. Endocrine, 2012, 41, 220-226.	2.3	47
139	Proteomic Analysis of Cerebrospinal Fluid from Obese Women with Idiopathic Intracranial Hypertension: A New Approach for Identifying New Candidates in the Pathogenesis of Obesity. Journal of Neuroendocrinology, 2012, 24, 944-952.	2.6	13
140	Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. Journal of Cellular Physiology, 2012, 227, 2352-2362.	4.1	69
141	Diabetes Is the Main Factor Accounting for Hypomagnesemia in Obese Subjects. PLoS ONE, 2012, 7, e30599.	2.5	60
142	TNF-α system and lung function impairment in obesity. Cytokine, 2011, 54, 121-124.	3.2	17
143	Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 104-110.	2.4	25
144	Erythropoietin protects retinal pigment epithelial cells against the increase of permeability induced by diabetic conditions: Essential role of JAK2/ PI3K signaling. Cellular Signalling, 2011, 23, 1596-1602.	3.6	41

#	Article	IF	CITATIONS
145	Prevalence and risk factors accounting for true silent myocardial ischemia: a pilot case-control study comparing type 2 diabetic with non-diabetic control subjects. Cardiovascular Diabetology, 2011, 10, 9.	6.8	35
146	Fenofibric Acid Reduces Fibronectin and Collagen Type IV Overexpression in Human Retinal Pigment Epithelial Cells Grown in Conditions Mimicking the Diabetic Milieu: Functional Implications in Retinal Permeability. , 2011, 52, 6348.		58
147	Measuring Permeability in Human Retinal Epithelial Cells (ARPE-19): Implications for the Study of Diabetic Retinopathy. Methods in Molecular Biology, 2011, 763, 179-194.	0.9	19
148	Phagocytic Activity Is Impaired in Type 2 Diabetes Mellitus and Increases after Metabolic Improvement. PLoS ONE, 2011, 6, e23366.	2.5	160
149	LIPOPOLYSACCHARIDE-BINDING PROTEIN AND SOLUBLE CD14 IN THE VITREOUS FLUID OF PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2010, 30, 345-352.	1.7	14
150	Type 2 diabetes impairs pulmonary function in morbidly obese women: a case–control study. Diabetologia, 2010, 53, 1210-1216.	6.3	31
151	Effect of intensive insulin therapy on macular biometrics, plasma VEGF and its soluble receptor in newly diagnosed diabetic patients. Diabetes/Metabolism Research and Reviews, 2010, 26, 386-392.	4.0	10
152	Insulin resistance is related to impaired lung function in morbidly obese women: a case–control study. Diabetes/Metabolism Research and Reviews, 2010, 26, 639-645.	4.0	26
153	Iron Overload in Diabetic Retinopathy: A Cause or a Consequence of Impaired Mechanisms?. Experimental Diabetes Research, 2010, 2010, 1-8.	3.8	37
154	Metabolic Fingerprints of Proliferative Diabetic Retinopathy: An ¹ H-NMR–Based Metabonomic Approach Using Vitreous Humor. , 2010, 51, 4416.		88
155	The Retinal Pigment Epithelium: Something More than a Constituent of the Blood-Retinal Barrier—Implications for the Pathogenesis of Diabetic Retinopathy. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-15.	3.0	337
156	New Pathogenic Candidates for Diabetic Macular Edema Detected By Proteomic Analysis. Diabetes Care, 2010, 33, e92-e92.	8.6	13
157	Neurodegeneration: An early event of diabetic retinopathy. World Journal of Diabetes, 2010, 1, 57.	3.5	118
158	Advances in the Medical Treatment of Diabetic Retinopathy. Diabetes Care, 2009, 32, 1556-1562.	8.6	124
159	Normoalbuminuric Type 1 Diabetic Patients with Retinopathy Have an Impaired Tubular Response to Desmopressin: Its Relationship with Plasma Endothelin-1. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2060-2065.	3.6	4
160	Lower Zinc-α2-Glycoprotein Production by Adipose Tissue and Liver in Obese Patients Unrelated to Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4499-4507.	3.6	95
161	Gene expression of paired abdominal adipose AQP7 and liver AQP9 in patients with morbid obesity. Metabolism: Clinical and Experimental, 2009, 58, 1762-1768.	3.4	45
162	Glucose abnormalities in nonâ€alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. Diabetes/Metabolism Research and Reviews, 2009, 25, 403-410.	4.0	26

#	Article	IF	CITATIONS
163	Effects of high glucose concentration on the barrier function and the expression of tight junction proteins in human retinal pigment epithelial cells. Experimental Eye Research, 2009, 89, 913-920.	2.6	62
164	Apolipoprotein A1 Is Overexpressed in the Retina of Diabetic Patients. American Journal of Ophthalmology, 2009, 147, 319-325.e1.	3.3	65
165	High glucose concentration leads to differential expression of tight junction proteins in human retinal pigment epithelial cells. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2009, 56, 53-58.	0.8	21
166	Growth Factors in the Diabetic Eye. Frontiers in Diabetes, 2009, , 109-123.	0.4	1
167	Diabetes Is an Independent Risk Factor for Severe Nocturnal Hypoxemia in Obese Patients. A Case-Control Study. PLoS ONE, 2009, 4, e4692.	2.5	29
168	Factors accounting for high ferritin levels in obesity. International Journal of Obesity, 2008, 32, 1665-1669.	3.4	62
169	Response to Heish et al American Journal of Gastroenterology, 2008, 103, 488-488.	0.4	0
170	Expression of Erythropoietin and Its Receptor in the Human Retina. Diabetes Care, 2008, 31, 1189-1194.	8.6	93
171	Elevation of Apolipoprotein A-I and Apolipoprotein H Levels in the Vitreous Fluid and Overexpression in the Retina of Diabetic Patients. JAMA Ophthalmology, 2008, 126, 1076.	2.4	67
172	Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Molecular Vision, 2008, 14, 1496-502.	1.1	57
173	Lower Somatostatin Expression Is an Early Event in Diabetic Retinopathy and Is Associated With Retinal Neurodegeneration. Diabetes Care, 2007, 30, 2902-2908.	8.6	170
174	Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C. American Journal of Gastroenterology, 2007, 102, 2189-2195.	0.4	40
175	Deficit of Somatostatin in the Vitreous Fluid of Patients With Diabetic Macular Edema. Diabetes Care, 2007, 30, 725-727.	8.6	39
176	Fenofibrate for diabetic retinopathy. Lancet, The, 2007, 370, 1667-1668.	13.7	40
177	Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. Expert Opinion on Investigational Drugs, 2007, 16, 1209-1226.	4.1	43
178	Erythropoietin Is Expressed in the Human Retina and It Is Highly Elevated in the Vitreous Fluid of Patients With Diabetic Macular Edema. Diabetes Care, 2006, 29, 2028-2033.	8.6	124
179	Serum markers of vascular inflammation in dyslipemia. Clinica Chimica Acta, 2006, 369, 1-16.	1.1	47
180	Sustained Virological Response Correlates With Reduction in the Incidence of Glucose Abnormalities in Patients With Chronic Hepatitis C Virus Infection. Diabetes Care, 2006, 29, 2462-2466.	8.6	118

#	Article	IF	CITATIONS
181	Intravitreous hepatocyte growth factor in patients with proliferative diabetic retinopathy: A case-control study. Diabetes Research and Clinical Practice, 2006, 71, 36-44.	2.8	25
182	Iron Deficiency in Obese Postmenopausal Women. Obesity, 2006, 14, 1724-1730.	3.0	110
183	Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy. Current Diabetes Reviews, 2006, 2, 71-98.	1.3	324
184	Soluble transferrin receptors and ferritin in Type 2 diabetic patients. Diabetic Medicine, 2005, 22, 97-101.	2.3	40
185	Somatostatin Molecular Variants in the Vitreous Fluid: A comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care, 2005, 28, 1941-1947.	8.6	56
186	Lipoprotein(a) as a Risk Factor for Cardiovascular Mortality in Type 2 Diabetic Patients: A 10-year follow-up study. Diabetes Care, 2005, 28, 931-933.	8.6	26
187	Usefulness of Homeostasis Model Assessment for Identifying Subjects at Risk for Hypoglycemia Failure during the Insulin Hypoglycemia Test. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3408-3412.	3.6	7
188	Albumin Excretion Rate Is Not Affected by Asymptomatic Urinary Tract Infection: A prospective study. Diabetes Care, 2004, 27, 1565-1569.	8.6	12
189	Hepatocyte Growth Factor in the Vitreous Fluid of Patients With Proliferative Diabetic Retinopathy: Its relationship with vascular endothelial growth factor and retinopathy activity. Diabetes Care, 2004, 27, 287-288.	8.6	9
190	High Prevalence of Glucose Abnormalities in Patients With Hepatitis C Virus Infection: A multivariate analysis considering the liver injury. Diabetes Care, 2004, 27, 1171-1175.	8.6	183
191	Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection. Diabetes Care, 2004, 27, 2669-2675.	8.6	53
192	CD4-CD8 and CD28 Expression in T Cells Infiltrating the Vitreous Fluidin Patients With Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2004, 122, 743.	2.4	36
193	INTRAVITREOUS LEPTIN CONCENTRATIONS IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2004, 24, 30-35.	1.7	11
194	Biological Variation of Lipoprotein(a) in a Diabetic Population. Analysis of the Causes and Clinical Implications. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1075-80.	2.3	8
195	Free insulin-like growth factor 1 in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case-control study. Clinical Science, 2003, 104, 223-230.	4.3	8
196	Free insulin-like growth factor 1 in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case-control study. Clinical Science, 2003, 104, 223.	4.3	21
197	Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Medical Science Monitor, 2003, 9, CR114-9.	1.1	6
198	Deficit of Somatostatin-Like Immunoreactivity in the Vitreous Fluid of Diabetic Patients: Possible role in the development of proliferative diabetic retinopathy. Diabetes Care, 2002, 25, 2282-2286.	8.6	58

#	Article	IF	CITATIONS
199	Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. American Journal of Ophthalmology, 2002, 134, 376-382.	3.3	84
200	V804M RET mutation and familial medullary thyroid carcinoma: Report of a large family with expression of the disease only in the homozygous gene carriers. Surgery, 2002, 131, 509-514.	1.9	44
201	Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetic Medicine, 2002, 19, 655-660.	2.3	40
202	Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: Effect of treatment with interferon. Translational Research, 2001, 137, 38-42.	2.3	48
203	Relationship of Lipoprotein(a) and Its Phenotypes with the Albumin Excretion Rate in Diabetic Patients: A Multivariate Analysis. Nephron, 2000, 85, 27-33.	1.8	12
204	False-Positive Results of Basal and Pentagastrin-Stimulated Calcitonin in Non-Gene Carriers of Multiple Endocrine Neoplasia Type 2A. Thyroid, 1997, 7, 51-54.	4.5	12
205	Transforming growth factorâ€beta 1: A new factor reducing hepatic SHBG production in liver fibrosis. Journal of Cellular Physiology, 0, , .	4.1	1